Protocol Builder

A GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Works by mimicking the incretin hormone GLP-1 to regulate appetite and blood sugar.

A dual GLP-1/GIP receptor agonist FDA-approved for type 2 diabetes (Mounjaro) and weight management (Zepbound). Targets two incretin pathways for potentially greater efficacy than GLP-1 alone.

An investigational triple agonist targeting GLP-1, GIP, and glucagon receptors. In clinical trials showing potentially the highest weight loss of any peptide studied to date.

A modified fragment (amino acids 177–191) of human growth hormone specifically designed to stimulate fat metabolism without the growth-promoting effects of full HGH.

A synthetic analog of α-MSH that activates melanocortin receptors, producing skin tanning, appetite suppression, and increased libido. Also studied for its fat loss and metabolic effects.

A modified growth hormone-releasing hormone (GHRH) analog with a short half-life that produces pulsatile GH release, mimicking the body's natural rhythm.

A long-acting GHRH analog that binds to albumin in the blood, providing sustained growth hormone elevation over 6–8 days rather than pulsatile release.

A selective growth hormone secretagogue that stimulates GH release from the pituitary without significantly affecting cortisol or prolactin levels, making it one of the mildest GH peptides.

A 29-amino acid analog of natural GHRH. One of the first GH-releasing peptides studied and one of the few that has been FDA-approved (for pediatric GH deficiency, since discontinued).

A potent growth hormone secretagogue that stimulates GH release through the ghrelin receptor. Produces strong GH pulses but also increases hunger and cortisol more than Ipamorelin.

One of the earliest GH secretagogues studied. Produces significant GH release and is known for its strong appetite-stimulating effects through ghrelin receptor activation.

An orally-active, non-peptide growth hormone secretagogue that mimics ghrelin. Provides sustained GH elevation over 24 hours and is taken by mouth rather than injection.

An FDA-approved GHRH analog specifically indicated for reducing visceral adipose tissue (belly fat) in HIV patients with lipodystrophy. Produces physiological GH pulses.

A synthetic version of a naturally occurring 43-amino acid peptide present in virtually all human cells. Plays a key role in cell migration, blood vessel formation, muscle flexibility, and tissue repair.

A synthetic peptide analog of α-MSH that acts on melanocortin receptors in the brain. FDA-approved (as Vyleesi) for hypoactive sexual desire disorder. Also studied for its effects on energy and performance.

A 15-amino acid peptide derived from a protein found in gastric juice. Widely studied for its tissue-healing and anti-inflammatory properties across multiple body systems.

A tripeptide derived from alpha-melanocyte-stimulating hormone (α-MSH). Possesses potent anti-inflammatory properties without the tanning effects of full-length α-MSH.

The only human cathelicidin antimicrobial peptide. Part of the innate immune system with broad-spectrum antimicrobial activity against bacteria, viruses, and fungi.

A 28-amino acid peptide naturally produced by the thymus gland. Plays a critical role in immune system maturation and function. Approved in over 35 countries for immune support (marketed as Zadaxin).

A peptide complex extracted from the thymus gland. Studied extensively in Russia for immune restoration, particularly in aging populations and those with immune deficiencies.

A naturally occurring copper-binding tripeptide that declines with age. Involved in wound healing, collagen synthesis, and has been shown to influence the expression of over 4,000 genes.

The base tripeptide (without copper) that naturally occurs in human plasma. Studied for hair follicle stimulation and wound healing. Levels decline significantly with age.

A peptide studied for its ability to activate the Wnt/β-catenin signaling pathway in hair follicles, potentially promoting new hair growth and preventing further loss.

A synthetic analog of the naturally occurring immunomodulatory peptide tuftsin. Developed in Russia as an anxiolytic (anti-anxiety) peptide with nootropic properties. Approved in Russia as a prescription medication.

A synthetic peptide derived from ACTH (adrenocorticotropic hormone). Developed in Russia as a nootropic and neuroprotective agent. Enhances BDNF expression. Approved in Russia for cognitive disorders and stroke recovery.

A naturally occurring neuropeptide that promotes delta wave sleep (deep sleep). Studied for its effects on sleep architecture, stress response, and pain modulation.

A synthetic tetrapeptide (Ala-Glu-Asp-Gly) studied for its ability to activate telomerase, the enzyme that maintains telomere length. Developed by Russian gerontologist Vladimir Khavinson.

A mitochondria-derived peptide that regulates metabolic homeostasis. Acts as an exercise mimetic, improving insulin sensitivity and metabolic function at the cellular level.